ClinicalTrials.gg
RecruitingNCT06687070Updated Jul 21, 2026

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

A Phase 1 interventional study of APG -2449 and PLD in Platinum-resistant Recurrent Ovarian Cancer and Advanced Solid Tumor, sponsored by Ascentage Pharma Group Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 394 studies in Ovarian Neoplasms with a site in China — 200 open to participants now, 232 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
153rd of 321
90 · median 83
Started
2024
with 53 others
Phase 1
70 of 394
37 open now
Primary completion
2027-05
later than 128 of 231 live
Registered
287th of 394
by date

Among the 394 studies in Ovarian Neoplasms with a site in China, this one is the 153rd largest by planned enrollment of the 321 interventional ones that give a count, is one of 54 that started in 2024, is one of 70 in phase 1, reaches primary completion later than 128 of the 231 other live ones, and was the 287th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

200 of the 394 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

195 more — sign in →

All 200 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 394 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.

Read the detailed description

Part A: To evaluate the safety of APG-2449 monotherapy in patients with advanced solid tumors.

Part B: To evaluate the safety, tolerability, and efficacy of APG-2449 combined with PLD in the treatment of ovarian cancer.

03

Conditions studied

  • Platinum-resistant Recurrent Ovarian Cancer
  • Advanced Solid Tumor

Browse trials for

Keywords

  • APG-2449
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Part A: No gender limitation. Patients with and/or cytologically confirmed ALK/ROS1 gene fusion positive non-small cell lung cancer and various advanced tumors.

    Part B: Female only. Histologically proven ovarian epithelial, fallopian tube, or primary peritoneal carcinoma.

  2. At least one measurable tumor lesion.
  3. score is 0\~1.
  4. of ≥3 months.
  5. AE caused by previous treatment must recover to ≤ grade 1.
  6. Sufficient bone marrow, liver, kidney and coagulation function.
  7. Female patients must be in a non-pregnant and non-lactating state.
  8. Able to understand and willing to sign .
  9. Patients are required to provide fresh or archived tumor tissue samples prior to treatment.

Exclusion criteria

Exclusion Criteria:

  1. Undergone major surgery or major trauma within 28 days before first dose or a diagnostic within 14 days before first dose.
  2. Received systemic antitumor drugs, including drugs.
  3. Received radiotherapy within 14 days before first dose.
  4. Previous treatment with FAK inhibitors.
  5. Have tumors at positions other than existing ovarian cancer or of other histological types within 3 years before first dose.
  6. Known active central nervous system (CNS) and/or cancerous meningitis.
  7. Major cardiovascular and cerebrovascular disease occurred within 6 months before first dose.
  8. Patients with pleural effusion, pericardial effusion, or ascites requiring puncture, drainage, or having received drainage within 1 month before first dose.
  9. Malabsorption syndrome, or inability to take medications orally.
  10. Severe gastrointestinal disease.
  11. Any serious or uncontrolled systemic disease; Various chronic active infections.
  12. Allergy to APG-2449 or PLD and its drug components.
  13. Previous cumulative doses of anthracyclines ≥550 mg/m\^2.
  14. Patients using a moderately potent , CYP2C9, or CYP2C19 inhibitor/inducer or P-gp inhibitor within a week before first dose. Patients using CYP3A4 substrates and the drugs of a narrow treatment window within a week before first dose.
  15. Other factors that, in the investigator's judgment, should prevent the patient from entering the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    APG -2449 Monotherapy

    Part A: Monotherapy for advanced solid tumors.

    Drug: APG -2449

  • Experimental
    APG -2449 combined with PLD

    Part B: Dose exploration and expansion of APG-2449 combined PLD.

    Drug: APG -2449 · Drug: PLD

Interventions

  • DrugAPG -2449

    Orally once a day(QD), every 28 days as a cycle.

  • DrugPLD

    Injected on the first day of each cycle, every 28 days as a cycle.

06

What researchers measure

Primary outcomes

  1. Treatment-related adverse events per NCI-CTCAE version 5.0.

    The number and frequency of adverse events of test drug will be assessed according to CTCAE v5.0.

    Time frame: Up to 1 year

  2. Dose Limiting Toxicity(DLT).

    DLT will be defined based on the rate of drug-related grade 3 to 5 adverse events experienced within the first 4 weeks of study treatment. These will be assessed per NCI-CTCAE version 5.0.

    Time frame: Up to 28 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for May 2027, 29 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 29 months is below that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 13, 2024
StartActual
Dec 17, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2028
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06687070
Responsible party
Sponsor
First posted
Nov 13, 2024
Start date
Dec 17, 2024
Primary completion
May 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Jul 21, 2026

Study contacts

Yifan Zhai, M.D., Ph.D.
Contact
yzhai@ascentage.com
+86-20-28068501
Wentao Pan, Ph.D.
Contact
Wentao.Pan@ascentage.com
Jundong Li, M.D.
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion